



**Office of the Vice President
for Research**

Institutional Biosafety Committee

Student Faculty Center, 3340 N Broad Street, Suite 427
Philadelphia PA 19140

Phone: (215) 707-9741 **Email:** ibc@temple.edu

TEMPLE UNIVERSITY
INSTITUTIONAL BIOSAFETY COMMITTEE
IBC Meeting Minutes- Online Meeting
July 15, 2025 12:02 pm

Members

X	Black, Dr. Mark- Community Member
X	Bradley, Carlos- Community Member
X	Culmer-Butler, Dr. Dorian- Animal Containment Expert
X	Escalante, Dr. Ananias- Scientist
X	Forste, Dr. Dawn- Animal Containment Expert
X	Lupinski, Gregory- EHRS Executive Director
X	Mettus, Richard- Senior Health & Safety Specialist
	Mobo, Dr. Ben Hur Jr.- Occupational Health Administrator
X	Moore, Claudia- IACUC Asst. Director
X	Murray, Krista- IBC Assistant Director
X	Pultro, Mary- IBC Sr. Coordinator
X	Sariyer, Dr. Ilker- IBC Vice-Chair, Scientist
X	Sawaya, Dr. Bassel- Scientist
X	Sulistijo, Dr. Endah- University Biosafety Officer
X	Tsygankov, Dr. Alexander- IBC Chair, Scientist
X	Whelan, Dr. Kelly- Scientist
X	Wimmer, Dr. Mathieu- Scientist

X= Present

Quorum was met for this meeting.

Guests

Baglia, Frank- Senior Health & Safety Specialist
Collyer, Eileen- Associate Health & Safety Specialist
Hao, Lanping- Associate Health & Safety Specialist
Khan, Sabina- Senior Health & Safety Specialist
Slupianek, Dr. Artur- Senior Director of Research Regulatory Affairs
Wright, Simone- IBC Analyst

I. Announcements

Ms. Murray announced that reappointment letters for the IBC members are being completed. With the reappointment, all members will be asked to complete the CITI IBC Membership training online. This will help meet the NIH *Guidelines* requirements for training of committee members. The link will be sent out to the membership.

II. Other Business

One protocol amendment was reviewed and approved by Designated Reviewers since the last meeting:

Rogers	11132	Amendment	Approved 6/30/2025
Annual update and change of PI for the Flow Cytometry Core Facility to Dr. Vincent Tam due to Dr. Rogers' retirement.			

III. Minutes Reviewed

Minutes from the June 17, 2025 meeting were reviewed. One edit was requested to correct Richard Mettus's job title. The motion to approve the minutes pending edit was made and approved unanimously.

IV. Protocols Reviewed

PI: Kutlu, Munir	Reg: 11240	Activity: Amendment	NIH: III-D-4	BSL: 1
Title: Predicting Maladaptive Aversive Learning Via Computational Modeling of Insular Single-Cell Ensemble Activity Patterns				
Overview: Add additional AAVs for neuro injections as previously approved.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Procedures were previously approved, just obtaining new AAVs.				
Final Action: approved				

PI: Kaminski, Rafal	Reg.: 11250	Activity: Amendment	NIH: III-D-1, 2, 3	BSL: 2
Title: Developing and Validating CRISPR-Based Anti-Viral Approaches				
Overview: Use a CRISPR-based approach to disable HSV-1 and HSV-2 genes, resulting in virus attenuation in vivo for Dr. Jensen. CRISPR-treated breast cancer cells will be clonally expanded, and single-cell gene knockout clones will be identified by DNA analysis for Dr. Boriello.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Need to clarify the fixative to be used for flow cytometry, confirm the rooms to be used, update the personnel list in the Exposure Control Plan, and add new cell line to the protocol.				
Final Action: modifications required				

PI: Wang, Ross	Reg.: 11111	Activity: Amendment	NIH: III-D-4	BSL: 2
Title: I. Chemical Probes to Identify Key Proteins in Human Cells that Mediate Cancer, Neuron, or Inflammatory Diseases. II. Invention of Peptides or Protein Conjugates for Protein-Protein Interactions				
Overview: The isolation and culture of primary murine neurons which are then treated with lab-synthesized fluorescent compounds for analysis and imaging.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Need to clarify room numbers. Need to indicate who will perform cage changes in SOP 1.0.				
Final Action: modifications required				

PI: Kutlu, Munir	Reg.: 11240	Activity: Amendment	NIH: III-D-4	BSL: 1
Title: Predicting Maladaptive Aversive Learning Via Computational Modeling of Insular Single-Cell Ensemble Activity Patterns				
Overview: Add additional AAVs for neuro injections as previously approved.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Procedures were previously approved, just obtaining new AAVs.				
Final Action: approved				

PI: Stanley, Robert	Reg.: 11261	Activity: Amendment	NIH: III-E-1	BSL: 1
Title: iFADS- Dually Fluorescent Reporters of Metabolic Flavoprotein Redox				
Overview: Adding two bacterial plasmids for protein overexpression				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Procedures were previously approved, just obtaining new plasmids.				
Final Action: approved				

PI: Rajadhyaksha, Anjali	Reg.: 11172	Activity: Amendment	NIH: III-D-4; III-E-3	BSL: 1
Title: The Neurobiological and Neurocircuitry Effects of Drugs of Abuse; Mouse Breeding Protocol				
Overview: AAV will be used for stereotaxic injections as previously approved for behavioral analyses.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices.				
Final Action: approved				

PI: Grana, Xavier	Reg.: 11160	Activity: Annual Renewal	NIH: III-D-1, 2, 3; III-E-1	BSL: 2
Title: 1. Unraveling the Complexity of PP2A/B55 Substrate Specificity, a Major Eukaryote Ser/Thr Phosphatase. 2. Role of PP2A in Cancer				
Overview: Additional transfection lentiviral plasmids for use in HEK293T cells.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Use in procedures as previously approved.				
Final Action: approved				

V. Old Business
None

VI. New Business
None

VII. Adjournment
The motion to adjourn the meeting was approved unanimously; the meeting adjourned at 12:51 pm.

Respectfully submitted,

Krista Murray

Krista Murray
Institutional Biosafety Committee Assistant Director